DAY 1, 21st October 2019 I 10:30 a.m -12:30 p.m

Satellite workshop - for all participants
Future vaccine manufacturing - hosted by Imperial College London's Future Vaccine Manufacturing Hub & BactiVac

Chair: Dr. Cal MacLennan
Senior Program Officer, Enteric & Diarrheal Diseases, Bill & Melinda Gates Foundation (BMGF)

Dr. MacLennan is lead for Bacterial Vaccines in the Enteric and Diarrheal Diseases Team at BMGF. He was previously Head of Exploratory at the Novartis Vaccines Institute for Global Health, and directs the BactiVac Bacterial Vaccinology Network.

Co-chair: Dr. Ben Pierce
Operations Manager, Future Vaccine Manufacturing Research Hub

Dr. Pierce is Operations Manager for the Future Vaccine Manufacturing Research Hub (FVMR), within Imperial College London, which researches innovative and more cost-effective vaccines for populations in developing countries. FVMR comprises eight UK-based institutes, the MSD Wellcome Trust Hilleman Laboratories, Vabiotech, Uganda Viral Research Institute, Dalian Hissen, and Incepta.

Dr. Dat Tuan Do
General Director, VABIOTECH

Dr. Dat is President of Company for Vaccine and Biological Production (VABIOTECH) in Vietnam. In this position, he manages all VABIOTECH's business and R&D activities, including research and development of new vaccine and biological products and expansion of vaccine business in the Vietnamese market as well as the global market.

Dr. Jon Cuccui
Associate Professor, The London School of Hygiene & Tropical Medicine (LSHTM)

Dr. Cuccui is a Molecular Microbiologist who currently works on the discovery, exploitation and fine tuning of bacterial N-linked glycosylation systems for the production of glycan-based vaccines. His group investigates how best to utilise these systems for the benefit of both human and animal health.

Dr. Constantino López-Macías
Head, Medical Research Unit on Immunochemistry at the Specialties Hospital, National Medical Centre "Siglo XXI" of the Mexican Social Security Institute

Professor López-Macías is an Immunologist whose research is focused on the mechanisms involved in the generation of long lasting Immunity, this has led to the development of several new vaccines against diseases caused by Salmonella and Influenza, and novel adjuvant platforms based on plant viruses and bacterial outer membrane proteins.

DAY 1, 21st October 2019 I 2:00 p.m - 3:30 p.m

Satellite symposium - for all participants
Responsible innovation: cost-effective manufacturing and economies of scale
Hosted by DCVMN Premium Partners

Chair: Dr. Ted Prusik
Co-founder and Senior Vice President, Temptime

Dr. Prusik's inventions helped create Temptime's technology which helps global health organizations monitor the temperature of vaccines and other biologics to prevent administration of vaccines compromised by high levels of heat or cold. He holds a PhD in chemical physics from New York University. Temptime is now part of Zebra Technologies.

Co-chair: Dr. Mats Lundgren
Director, GE Healthcare Life Sciences

Dr. Lundgren has more than 25 years of experience in vaccinology. As Customer Applications Director at GE, he helps companies implement modern processes with the goal of achieving more efficient production and higher vaccine quality.

Mr. Tim Kram
General Manager, Rommelag, USA

Mr. Kram is an Engineer and pharmaceutical business development professional. For the past 16 years, he has worked with companies to develop aseptic product fill/finish solutions using Blow/Fill/Seal technology. For ten years he has worked to introduce temperature sensitive biotech and vaccine products to BFS technology.

DAY 2, 22nd October 2019 I 09:00 a.m - 10:30 a.m

Plenary opening session

Chair: Ms. Mahima Datla
Managing Director, Biological E

Ms. Datla is the Managing Director of Biological E Limited, one of the leading vaccine manufacturers based in India. Over a career spanning 20 years, she has also held key positions in several public health organisations such as Gavi, DCVMN, GHIT and Hilleman Labs, representing her organisation and the DCVMN.

Co-chair: Dr. Maurício Zuma Medeiros
Director, Bio-Manguinhos / Fiocruz

Dr. Medeiros served as Executive Director of the Foundation for Scientific and Technological Development in Health (Fiotec) from 2011 to 2017. He is currently director of Bio-Manguinhos / Fiocruz. He has 30 years of management experience, focused on results and management solutions for the advancement of public health.

Dr. Luiz Henrique Mandetta
Minister of Health of Brazil

Dr. Mandetta is a pediatric orthopedist with post-graduate specialization in service management and health care. He is a member of both the fiscal council of the Medical Doctor's Cooperative and the Special Commission to Combat Zika Virus. Previously, he was Municipal Secretary of Health of Campo Grande and Federal Congressman.

Dr. Nisia Trindade Lima
President, Fiocruz

Dr. Trindade Lima became President of Fiocruz in 2017 and is the first woman to occupy this position in 116 years of institutional history. At Fiocruz, she previously served as Vice President of Education, Information and Communication, Director of Casa de Oswaldo Cruz and Scientific Editor of Fiocruz Press.

Dr. Tedros A. Ghebreyesus
WHO Director-General

A globally recognised health scholar, researcher, and diplomat, Dr. Tedros was elected WHO Director-General in 2017. Immediately after taking office, Dr. Tedros outlined five key priorities for the Organization: universal health coverage; health emergencies; women's, children's and adolescents' health; health impacts of climate and environmental change; and a transformed WHO.

Dr. Carissa F. Etienne
PAHO Director

Dr. Etienne has served as the PAHO Director since 2013, as well as the Regional Director of WHO for the Region of the Americas. Previously, she was Assistant Director-General for Health Systems and Services at WHO in Geneva, Switzerland.

DAY 2, 22nd October 2019 I 11:00 a.m - 12:30 p.m

Innovation for immunization

Chair: Dr. Nisia Trindade Lima
President, Fiocruz

Dr. Trindade Lima became President of Fiocruz in 2017 and is the first woman to occupy this position in 116 years of institutional history. At Fiocruz, she previously served as Vice President of Education, Information and Communication, Director of Casa de Oswaldo Cruz and Scientific Editor of Fiocruz Press.

Co-chair: Dr. Alexander Precioso
Director, Clinical Trials and Pharmacovigilance Division, Instituto Butantan

Dr. Precioso is the Director of the Clinical Trials and Pharmacovigilance Division of Instituto Butantan. Dr. Precioso is also the Vice-President of the Executive Committee of the DCVMN and member of the Scientific Organizing Committee of the Global Vaccine and Immunization Research Forum (GVIRF).

Dr. Kate O'Brien
Director, Department of Immunization, Vaccines and Biologicals, WHO

Dr. O'Brien joined WHO in January 2019, after a career at Johns Hopkins School of Public Health, to lead the Department of Immunization, Vaccines and Biologicals (IVB). She leads IVB to achieve immunization impact, effectiveness and optimization through global strategy and agenda development, policy, research, innovation, and programme optimization.

Dr. Ruben Donis
Chief Science Officer, Influenza and Emerging Infectious Diseases Division, Biomedical Advanced Research and Development Authority (BARDA) U.S. Department of Health and Human Services

Dr. Donis is the Chief Science Officer of the Influenza and Emerging Infectious Diseases Division of BARDA, overseeing advanced development of medical countermeasures for pandemic influenza and emerging diseases. Previously, Dr. Donis served as Associate Director and Chief of the Molecular Virology and Vaccines Branch, in the Influenza Division, US CDC.

Mr. Frederik Kristensen
Deputy CEO, CEPI

Before joining CEPI, Mr. Kristensen was a senior advisor on innovation at WHO in Geneva, Switzerland, in the Family, Women, Children and Adolescents Cluster. He has previous experience in health economics, hospital management and the pharmaceutical industry. He is a medical doctor with a MPH/MBA degree from UC Berkeley.

Dr. David Kaslow
Vice President, Essential Medicines, PATH

Dr. Kaslow is Vice President for Essential Medicines, which includes the Drug Development Program and the PATH Center for Vaccine Innovation and Access (CVIA). Before joining PATH in 2012, he held key advisory positions with PATH's Malaria Vaccine Initiative (MVI) and the Bill & Melinda Gates Foundation.

DAY 2, 22nd October 2019 I 2:00 p.m - 3:00 p.m

Procurement and financing of vaccines

Chair : Mr. Sai Prasad
President, Quality Operations, Bharat Biotech

As President of quality operations, Mr. Prasad oversees all aspects of quality management including quality assurance, control, and management systems and is responsible for product development and commercialisation of vaccines and biologics. He has 25 years of experience in biotechnology, good manufacturing practice, operations and quality management.

Co-Chair: Mr. John Fitzsimmons
Chief of the Revolving Fund Special Program for Vaccine Procurement, PAHO

Mr. Fitzsimmons has focused his career in vaccine preventable diseases at WHO regional offices and the U.S. Centers for Disease Control & Prevention (CDC); working to ensure the uninterrupted supply of affordable vaccines in support of regional goals for polio eradication, measles and rubella elimination and introduction of new vaccines.

Dr. Jarbas Barbosa da Silva Junior
PAHO Assistant Director

Dr. Jarbas Barbosa da Silva Jr. was appointed Assistant Director of PAHO in 2018. Prior to joining PAHO, Dr. Barbosa served as the Director-President of Anvisa and Secretary for Health Surveillance and Secretary of Science, Technology and Strategic Supplies for the Ministry of Health in Brazil.

Ms. Etleva Kadilli
Director, UNICEF Supply Division

Ms. Kadilli is Director of UNICEF's Supply Division in Copenhagen, Denmark, overseeing UNICEF's global supply operations in development and emergency contexts, with an annual expenditure exceeding USD 3.4 billion. An Albanian national, Ms. Kadilli has worked for UNICEF for more than 20 years in various supply and programme operations roles.

Dr. Seth Berkley
CEO, Gavi, the Vaccine Alliance

A medical doctor and epidemiologist, Dr. Berkley joined Gavi as its CEO in 2011. Previously, he founded the International AIDS Vaccine Initiative (IAVI), serving as president and CEO for 15 years. Dr. Berkley holds undergraduate and medical degrees from Brown University and trained in internal medicine at Harvard University.

DAY 2, 22nd October 2019 I 3:00 p.m - 5:30 p.m

Voices & choices forum

DAY 2, 22nd October 2019 I 3:00 p.m – 4:00 p.m

Panel discussion I - Public market dynamics

Moderator: Ms. Nine Steensma
Director, Vaccine Markets, CHAI

Ms. Steensma serves as the Director of Vaccines Markets at the Clinton Health Access Initiative (CHAI). CHAI's Vaccines Markets Team provides business planning support to vaccine manufacturers, based on the premise that developing and manufacturing vaccines for low-income countries needs to be based on a commercially sustainable business proposition.

Mr. John Fitzsimmons
Chief of the Revolving Fund Special Program for Vaccine Procurement, PAHO

Mr. Fitzsimmons has focused his career in vaccine preventable diseases at WHO regional offices and the U.S. Centers for Disease Control & Prevention (CDC); working to ensure the uninterrupted supply of affordable vaccines in support of regional goals for polio eradication, measles and rubella elimination and introduction of new vaccines.

Ms. Etleva Kadilli
Director, UNICEF Supply Division

Ms. Kadilli is Director of UNICEF's Supply Division in Copenhagen, Denmark, overseeing UNICEF's global supply operations in development and emergency contexts, with an annual expenditure exceeding USD 3.4 billion. An Albanian national, Ms. Kadilli has worked for UNICEF for more than 20 years in various supply and programme operations roles.

Dr. Maurício Zuma Medeiros
Director, Bio-Manguinhos / Fiocruz

Dr. Medeiros served as Executive Director of the Foundation for Scientific and Technological Development in Health (Fiotec) from 2011 to 2017. He is currently director of Bio-Manguinhos / Fiocruz. He has 30 years of management experience, focused on results and management solutions for the advancement of public health.

Dr. Suresh Jadhav
Executive Director, Serum Institute of India

Dr. Jadhav is the Executive Director of Serum Institute of India and was DCVMN's President from 2003-2008. He is a board member of the European Vaccine Initiative, FastVac and HIP. He is active in several collaborative studies and has published more than 95 technical papers in national and international journals.

Dr. Dominic Hein
Head, Market Shaping, Gavi, the Vaccine Alliance

Dr. Hein heads up the market shaping team at Gavi, the Vaccine Alliance, in Geneva, Switzerland. Before joining Gavi in 2018, Dr. Hein spent 13 years at GSK Vaccines, based variously in Belgium, UK, USA and Japan. He is a medical doctor and holds an MBA from INSEAD.

DAY 2, 22nd October 2019 I 4:30 p.m - 5:30 p.m

Panel discussion II - Access to capital: Removing financial barriers for innovative manufacturing in developing countries

Moderator: Mr. Gerard Cunningham
Operating Partner, Adjuvant Capital

Mr. Cunningham is a vaccine development expert whose broad experience includes leadership roles at Merck and the Bill & Melinda Gates Foundation in new product planning, global marketing strategy and business development. He holds an MBA from the University of Michigan and MEng and MA from the University of Cambridge.

Ms. Jenny Yip
Managing Partner, Adjuvant Capital

Ms. Yip is Managing Partner of Adjuvant Capital, a dedicated global health investment fund and successor to the Global Health Investment Fund (GHIF). Adjuvant invests in late-stage global health products for infectious disease, maternal and child health. Ms. Yip was previously a Partner at the Gates Foundation Strategic Investment Fund.

Ms. Younbeen Kim
Executive Director & CEO, RIGHT Fund

Ms. Kim is the CEO of the RIGHT Fund, a Korea-based public-private-partnership between Korean Government, industry, and the Bill & Melinda Gates Foundation. Previously, she was head of Global Partnership, Research Operations at Novartis Institute for Tropical Diseases in Singapore. She holds BPharm and MBA degrees.

Ms. Jessica Martinez
Senior Program Officer, Life Sciences Partnerships, Bill & Melinda Gates Foundation (BMGF)

Ms. Martinez is a Senior Program Officer in the Life Sciences Partnerships team at BMGF. She supports collaborations with industry partners in Asia and leads sustainable financing initiatives. Ms. Martinez holds a BA in Molecular Biology from Princeton University and an M.A. in Business and International Affairs from Tufts University.

Mr. Sai Prasad
President, Quality Operations, Bharat Biotech

As President of quality operations, Mr. Prasad oversees all aspects of quality management including quality assurance, control, and management systems and is responsible for product development and commercialisation of vaccines and biologics. He has 25 years of experience in biotechnology, good manufacturing practice, operations and quality management.

Dr. Peter Khoury
President and CEO, Ology Bioservices

Dr. Khoury has spent 30 years in the vaccines and biologics industry with cross-sector experiences from BMGF, Merck and Baxter. While at the Gates Foundation, Peter led the expansion of industry engagement with the DCVM sector. He is currently CEO of Ology Bioservices, a biologics CDMO located in Florida.

DAY 3, 23rd October 2019 I 09:00 a.m -10:00 a.m

Innovative partnerships forum

Chair: Mr. Patrick Tippoo
Head of Science and Innovation, The Biovac Institute

Mr. Tippoo heads Science and Innovation at Biovac, in South Africa. He is a founding member and current Executive Director of the African Vaccine Manufacturing Initiative (AVMI) and has been a member of the DCVMN Executive Committee since 2014.

Co-Chair: Dr. Yeong-Ok Baek
CEO, EuBiologics

Dr. Baek has over 30 years of experience in the biotechnology industry. He founded EuBiologics Co., Ltd in 2010 and is currently the CEO. He is a graduate in Veterinary Medicine from Seoul National University and holds a PhD in Life Science from Korea University.

Mr. Rajinder Kumar Suri
Chief Executive - Biologicals, Panacea Biotec Ltd

Mr. Suri has over 40 years of experience in Pharmaceuticals & Biological products in India & International markets, with 22 years in top management, including four years on the Board of Directors of the Indian subsidiary of Sanofi Pasteur. He is a former Gavi-PPC member and former DCVMN Vice-President.

Dr. T. Anh Wartel
Head of Clinical Development and Regulatory, International Vaccine Institute (IVI)

Dr. T. Anh Wartel has over 20 years of experience in epidemiological and clinical research. She holds an MD degree from Paris Medical School (France) and post-graduate diploma in public health from University of Liverpool (UK). She's been involved in the development of multiple vaccines in pre- and post-licensure stages.

Mr. Rayasam Prasad
Senior CMC Advisor, Vaccine Development, Global Health, Bill & Melinda Gates Foundation (BMGF)

Before joining BMGF, Mr. Prasad was COO and President, Vaccines & Biologics at Biological E and a board member for Qualivax, a GSK-BE joint venture. Mr. Prasad's 40 years of experience include senior roles at Genentech, Chiron Novartis, Medimmune and Genzyme.

DAY 3, 23rd October 2019 I 10:30 a.m - 12:30 p.m

Gavea Ballroom A I Catalyzing product development of vaccine technology innovations: Vaccine Innovation Prioritization Strategy (VIPS)

Chair: Dr. Sotiris Missailidis
Deputy Director, Technological Development, Bio-Manguinhos

Prior to his current role, Dr. Missailidis was a Senior Visiting Researcher at the Laboratory of Hantavirus and Rickettsiosis at Oswaldo Cruz Institute. At Bio-Manguinhos, he was a biotechnologist in the Laboratory of Monoclonal Antibody. He holds a postdoctoral degree in pharmaceutical sciences and molecular biology from Nottingham and Cambridge Universities.

Co-chair: Mr. Darin Zehrung
Program Leader, Medical Devices and Health Technologies, PATH

In his 20 years at PATH, Mr. Zehrung has advanced many medical products that contribute to PATH's reputation as a health technology innovator in low-resource settings. He leads works in the areas of vaccine and pharmaceutical packaging, formulation and delivery technologies, supply chain innovations, and reproductive, maternal, and neonatal health.

Ms. Marion Menozzi-Arnaud
Senior Projects Specialist, Market Shaping Team, Gavi, the Vaccine Alliance

Ms. Menozzi-Arnaud works on strategic cross portfolio projects where she contributes to the identification of solutions for broad questions arising from market-based health commodity related challenges. Previously, she was Head of Pricing and Market Access, Biosimilars at Merck, and before that she spent 15+ years working as a management consultant.

Ms. Debra Kristensen
Director, Vaccine Technology Strategy and Policy, PATH

Ms. Kristensen is PATH's senior advisor on vaccine technologies including formulation, delivery and packaging, and supply systems and equipment innovations. She is a member of the Vaccine Innovation Prioritisation Strategy (VIPS) Alliance Working Group, the Immunization Agenda 2030 Research and Innovation Working Group, and WHO's Total Systems Effectiveness Steering Committee.

Dr. Birgitte Giersing
Technical Officer, Department of Immunizations, Vaccines and Biologics, WHO

Dr. Giersing is the Secretariat for the Product Development Vaccine Advisory Committee and the co-chair of WHO's Delivery Technologies Working Group. Dr. Giersing previously worked in private industry, and prior to that oversaw development of early stage malaria vaccine candidates at PATH before moving into private industry.

Panel discussion - How the Alliance Vaccine Innovation Prioritisation Strategy may help drive vaccine delivery innovations

Moderator: Dr. Dominic Hein
Head, Market Shaping, Gavi, the Vaccine Alliance

Dr. Hein heads up the market shaping team at Gavi, the Vaccine Alliance, in Geneva, Switzerland. Before joining Gavi in 2018, Dr. Hein spent 13 years at GSK Vaccines, based variously in Belgium, UK, USA and Japan. He is a medical doctor and holds an MBA from INSEAD.

Mrs. Ann Egede Ottosen
Contracts Manager, UNICEF Supply Division

Ms. Ottosen oversees global tendering, procurement and contracting of polio vaccines and novel vaccines, including for stockpiles. Before joining UNICEF in 2007, she was responsible for global sales of vaccines for a Danish government owned vaccine manufacturer as well as procurement of all vaccines for the Danish market.

Dr. David Kaslow
Vice President, Essential Medicines, PATH

Dr. Kaslow is Vice President for Essential Medicines, which includes the Drug Development Program and the PATH Center for Vaccine Innovation and Access (CVIA). Before joining PATH in 2012, he held key advisory positions with PATH's Malaria Vaccine Initiative (MVI) and the Bill & Melinda Gates Foundation.

Mr. Steven Gao
General Manager, Xiamen INNOVAX Biotech Co., Ltd.

Before joining Innovax, Mr. Gao worked as a Director and a Vice President for sales and marketing in the biopharma industry. During his ten years with Innovax, Mr. Gao held various key positions in quality control and sales and marketing before being promoted to General Manager of the company.

Mr. Sai Prasad
President, Quality Operations, Bharat Biotech

As President of quality operations, Mr. Prasad oversees all aspects of quality management including quality assurance, control, and management systems and is responsible for product development and commercialisation of vaccines and biologics. He has 25 years of experience in biotechnology, good manufacturing practice, operations and quality management.

Ms. Anna-Lea Kahn
Technical Officer, Department of Immunizations, Vaccines and Biologics, WHO

Ms. Anna-Lea Kahn works in the Expanded Program on Immunization (EPI) at the World Health Organization, focusing on logistics and innovation since 2014. Previously, she spent ten years in the research and policy team of the Polio Eradication Initiative.

DAY 3, 23rd October 2019 I 10:30 a.m -12:30 p.m

Gavea Ballroom B I Regulatory forum: Implementing regulatory convergence

Chair: Dr. Nora Dellepiane
Independent Consultant

Dr. Dellepiane has 40 years' experience in production and control of biological products. She headed the NCL in Argentina for 10 years and worked at WHO for 19 years. She now supports manufacturers and regulators to address challenges in the quality/regulation of biologicals, including providing training in this field.

Co-Chair: Mr. Samir Desai
President & Head Biologics, Zydus Cadila Healthcare Ltd.

Mr. Desai has more than 30 years of industry experience having handled sales, training, brand management, marketing and commercial operations. His current role includes commercial operations for vaccines and biologics and small molecules across specialties and geographies; business development; in & out licensing; portfolio planning; and liaising with external stakeholders.

Dr. Bernardo Luiz Moraes Moreira
Advisor to the Anvisa Director

Dr. Moreira graduated as a pharmacist and holds Master's & Doctoral degrees in biochemistry from Federal University of Rio de Janeiro. He joined Anvisa in 2007, where he served as CMC reviewer and also carried out GMP inspection of biological products. Currently, he's Advisor to Anvisa Director Dr. Alessandra Soares.

Ms. Carmen Rodriguez
Scientist, Group Lead, Vaccines Assessment Prequalification Team, WHO

Ms. Rodriguez has 29 years of experience in regulation of biologicals at the global level. She leads the Vaccines Assessment WHO Prequalification (PQ) team that evaluates vaccines and other biologicals submitted for PQ or risk/benefit assessment and post PQ monitoring activities to ensure their quality, safety and efficacy.

Ms. Alexandra Guta
Specialist, Quality Management Systems, PAHO

Ms. Guta works as a quality management systems specialist for the Pan American Health Organization/World Health Organization (PAHO/WHO) in support of the PAHO Revolving Funds. She oversees quality assurance processes and standards for the Revolving Funds (RFs) to improve access to quality-assured medicines, including vaccines.

Dr. Diadié Maïga
Regional Vaccine Regulation Officer, WHO Regional Office for Africa

Prior to joining WHO, Dr. Maïga served as a Pharmaceutical Systems Officer and Deputy General Director at the Malian Ministry of Health. Before that, he served as a Pharmaceutical Policy Advisor at the Haitian Ministry of Health. Dr. Maïga holds a BPharm and PhD.

Dr. Patrick Zuber
Group Lead, Global Vaccine Safety, WHO

Dr. Zuber leads Global Vaccine Safety activities at WHO headquarters and is the executive secretary of the Global Advisory Committee on Vaccine Safety. Through his leadership, WHO launched the Global Vaccine Safety Initiative, a global effort to ensure that everyone, everywhere who receives a vaccine can benefit from adequate pharmacovigilance.

DAY 3, 23rd October 2019 I 2:00 p.m – 4:00 p.m

Gavea Ballroom A I Future vaccines

Chair: Mrs. Lingjiang Yang
Manager of International Business and Cooperation, Chengdu Institute of Biological Products Co., Ltd. (CDIBP), CNBG

Mrs. Yang is responsible for all international cooperation development and management as well as international marketing. Her experience as the project coordinator of the WHO prequalification of live Japanese Encephalitis vaccine has given her insight into the global vaccine industry.

Co-chair: Mr. Weining Meng
Director, International Regulatory Affairs and Business, Sinovac Biotech

Mr. Meng joined Sinovac in 2007 where he worked as international regulatory manager and QA manager. Mr. Meng led the team that helped Sinovac's Hepatitis A vaccine achieve WHO prequalification in 2017: Sinovac's first vaccine to gain this status. Currently, Mr. Meng serves as Director, International Regulatory Affairs and Business.

Dr. Sarah Gilbert
Professor of Vaccinology, Oxford University/VaxHub

Professor Gilbert's chief research interest is the development of viral vectored vaccines that work by inducing strong and protective T and B cell responses. She is a co-founder of Vaccitech and now also works on vaccines for many different emerging pathogens, including Nipah, MERS, Lassa and CCHF.

Dr. Ben Pierce
Operations Manager, Future Vaccine Manufacturing Research Hub

Dr. Pierce is Operations Manager for the Future Vaccine Manufacturing Research Hub (FVMR), within Imperial College London, which researches innovative and more cost-effective vaccines for populations in developing countries. FVMR comprises eight UK-based institutes, the MSD Wellcome Trust Hilleman Laboratories, Vabiotech, Uganda Viral Research Institute, Dalian Hissen, and Incepta.

Dr. Cal MacLennan
Senior Program Officer, Enteric & Diarrheal Diseases, Bill & Melinda Gates Foundation (BMGF)

Dr. MacLennan is lead for Bacterial Vaccines in the Enteric and Diarrheal Diseases Team at BMGF. He was previously Head of Exploratory at the Novartis Vaccines Institute for Global Health, and directs the BactiVac Bacterial Vaccinology Network.

Dr. Raches Ella
Head, Business Development and Advocacy, Bharat Biotech

Dr. Ella is the Head of Business Development and Advocacy at Bharat Biotech. His area of specialty is in Rotavirus and Typhoid Conjugate vaccines. By training, he is a Clinical Trialist and is an alumnus of Emory and Johns Hopkins Universities.

Ms. Wendy Huang
Assistant to General Manager, Xiamen INNOVAX Biotech Co., Ltd

Ms. Huang joined Innovax in 2010. She has 9 years of experience in the vaccine industry and has participated in all stages of HPV vaccine development. Currently, Ms. Huang is the chief coordinator of the HPV vaccine product program and leads the WHO prequalification projects at Innovax.

Ms. Qian Zhang
Head of International Affairs, Beijing Minhai Biotechnology

Ms. Zhang heads technology licensing, international registration and export and international collaboration at Beijing Minhai Biotechnology Co., Ltd. She has developed vaccine business in 10 countries, primarily in Asia and Africa, and has participated in and led technology licensing and transfer of HDCV rabies vaccine, sIPV, fully liquid PENTA and MMRV.

Dr. Sanjeev Kumar
President, Zydus Cadila Healthcare Ltd.

Dr. Kumar has been Zydus Cadila's president for over 15 years. He holds a PhD in Immunology -Antigen processing and presentation from the National Institute of Immunology and an MSc in Biotechnology from Madurai Kamaraj University. Prior to joining Zydus Cadila, Dr. Kumar was a postdoctoral researcher at Vanderbilt University.

Dr. Kapil Maithal
Senior Vice President & Head – Vaccines, Zydus Cadila Healthcare Ltd.

Dr. Maithal is currently working as Senior Vice President and Head – Vaccines with Zydus Cadila, India. He has over two decades of experience in managing, strategizing and executing development of vaccines and biotherapeutics for global use. At Zydus he leads Vaccine R&D, technology transfer and Manufacturing (Drug Substance) teams.

DAY 3, 23rd October 2019 I 2:00 p.m – 4:00 p.m

Gavea Ballroom B I Vaccine market intelligence

Chair: Dr. Suresh Jadhav
Executive Director, Serum Institute of India

Dr. Jadhav is the Executive Director of Serum Institute of India and was DCVMN's President from 2003-2008. He is a board member of the European Vaccine Initiative, FastVac and HIP. He is active in several collaborative studies and has published more than 95 technical papers in national and international journals.

Co-Chair: Ms. Tania Cernuschi
Team Leader, Vaccine Supply, Technologies & Financing, WHO

Ms. Cernuschi leads WHO's work on vaccine supply, technologies and financing. She has 15 years of experience in the design and management of development programmes aimed at enhancing access to health technologies in resource-constrained settings. Before joining WHO, Ms. Cernuschi worked for Gavi, UNDESA, the Italian Government, UNICEF and NGOs.

Mrs. Ann Egede Ottosen
Contracts Manager, UNICEF Supply Division

Ms. Ottosen oversees global tendering, procurement and contracting of polio vaccines and novel vaccines, including for stockpiles. Before joining UNICEF in 2007, she was responsible for global sales of vaccines for a Danish government owned vaccine manufacturer as well as procurement of all vaccines for the Danish market.

Mr. John Fitzsimmons
Chief of the Revolving Fund Special Program for Vaccine Procurement, PAHO

Mr. Fitzsimmons has focused his career in vaccine preventable diseases at WHO regional offices and the U.S. Centers for Disease Control & Prevention (CDC); working to ensure the uninterrupted supply of affordable vaccines in support of regional goals for polio eradication, measles and rubella elimination and introduction of new vaccines.

Panel discussion - Leveraging market intelligence and global demand estimates to support DCVM investment decisions

Moderator: Dr. Suresh Jadhav
Executive Director, Serum Institute of India

Dr. Jadhav is the Executive Director of Serum Institute of India and was DCVMN's President from 2003-2008. He is a board member of the European Vaccine Initiative, FastVac and HIP. He is active in several collaborative studies and has published more than 95 technical papers in national and international journals.

Co-Chair: Ms. Tania Cernuschi
Team Leader, Vaccine Supply, Technologies & Financing, WHO

Ms. Cernuschi leads WHO's work on vaccine supply, technologies and financing. She has 15 years of experience in the design and management of development programmes aimed at enhancing access to health technologies in resource-constrained settings. Before joining WHO, Ms. Cernuschi worked for Gavi, UNDESA, the Italian Government, UNICEF and NGOs.

Mrs. Ann Egede Ottosen
Contracts Manager, UNICEF Supply Division

Ms. Ottosen oversees global tendering, procurement and contracting of polio vaccines and novel vaccines, including for stockpiles. Before joining UNICEF in 2007, she was responsible for global sales of vaccines for a Danish government-owned vaccine manufacturer as well as procurement of all vaccines for the Danish market.

Mr. Ed Baker
Senior Specialist, Market Shaping, Gavi, the Vaccine Alliance

Prior to joining Gavi in 2013, Mr. Baker worked for Merck Serono as Associate Director, Global Market Access & Pricing, and previously at IMS Health and Boston Consulting Group. He holds a Master's in Management and a Bachelor's in Molecular Biology from the University of Bath.

Mr. John Fitzsimmons
Chief of the Revolving Fund Special Program for Vaccine Procurement, PAHO

Mr. Fitzsimmons has focused his career in vaccine preventable diseases at WHO regional offices and the U.S. Centers for Disease Control & Prevention (CDC); working to ensure the uninterrupted supply of affordable vaccines in support of regional goals for polio eradication, measles and rubella elimination and introduction of new vaccines.

Mr. Lakshminarayana Neti
COO, Biological E

Mr. Neti has over 30 years of experience in business & technical operations, supply chain and R&D. Prior to joining Biological E, he was Director of Operations at Abbott. Academically a Mechanical Engineer, he holds an MBA in Finance from the Manchester Business School and a PGD in Patent Law.

Mr. Andrew Wong
Vice President Business Development, Shanghai Zerun Biotech Walvax

Mr. Wong heads business development and clinical research for Shanghai Zerun Biotech, a Walvax subsidiary, and manages international collaborations for Walvax. He helps advance Zerun's HPV-2/9 development. He received medical, graduate and management trainings in China, Canada and the U.S. and previously spent 12 years in drug research at Amgen.

DAY 3, 23rd October 2019 I 4:30 p.m – 5:30 p.m

Gavea Ballroom A I Closing session

Chair: Dr. Akira Homma
Senior Advisor, Bio-Manguinhos/ Fiocruz

Dr. Homma serves as Senior Scientific and Technological Advisor to Bio-Manguinhos. He is a Doctor of Veterinary Medicine, holds a DSci from the São Paulo University School of Medicine, and completed post-graduate studies in Virology at Baylor College of Medicine. Dr. Homma has published more than 60 scientific papers.

Co-Chair: Dr. Dat Tuan Do
General Director, VABIOTECH

Dr. Dat is President of Company for Vaccine and Biological Production (VABIOTECH) in Vietnam. In this position, he manages all VABIOTECH's business and R&D activities, including research and development of new vaccine and biological products and expansion of vaccine business in the Vietnamese market as well as the global market.

Dr. Mariângela Simão
Assistant Director-General, Access to Medicines and Health Products, WHO

Dr. Simão joined WHO in November 2017, as part of Dr Tedros Adhanom Ghebreyesus' leadership team.She previously worked for UNAIDS since September 2010 and prior to that, she worked for the Ministry of Health in Brazil as the Director of the Sexually Transmitted Diseases, HIV/ AIDS and Viral Hepatitis department.